AI Infrastructure Stocks To Watch Beyond Big Tech Burnout

Reports of burnout inside big AI and automation firms are clashing with promises of effortless productivity, and that gap is where investors should pay attention. Stress, reshuffles, and long hours can unsettle some companies while creating openings for others that handle the pressure better. This article unpacks that tension and highlights 3 stocks from our AI and Automation Technology screener that appear positively exposed to the current news flow.

The 3 stocks below are just a starting sample from this theme, and the full screen surfaced 27 more companies with equally compelling narratives that are not covered here. To go deeper into artificial intelligence and automation, head straight into the Artificial Intelligence (AI) and Automation Technology screener to identify, analyze, and focus on the highest conviction ideas.

Ouster (OUST)

Overview: Ouster is a San Francisco based lidar specialist that sells digital sensor kits and perception software used to give robots, vehicles, and smart infrastructure a precise 3D view of the world across automotive, industrial, robotics, and traffic management applications globally.

Operations: Ouster generates essentially all of its roughly US$205 million in revenue from the sale of lidar sensor kits, with reported sales concentrated in the United States and wider Americas.

Market Cap: US$3.1b

Investors watching the strain inside large AI firms may find Ouster interesting as a picks and shovels supplier to physical automation. The company pairs lidar hardware with software platforms like BlueCity traffic management and Gemini perception, giving it a role in smart infrastructure, robotics, and ADAS where automation is accelerating. Recent collaborations with NVIDIA, heavy equipment makers, and robotics partners show how Ouster is trying to embed its tech deeply into customer workflows. At the same time, the business is still loss making, carries funding and dilution risk, and trades on rich revenue multiples, which means expectations are high. For investors who can handle volatility, the combination of automation demand and execution risk makes Ouster a company some may choose to watch closely.

Ouster’s push to wire automation into real world hardware could be masking a more complicated story under the hood. Get the full context in the 3 key rewards and 3 important warning signs (2 are major!)

Build your own AI automation shortlist

Ouster and the two other stocks in this article all came out of a single screen, but the real edge is in shaping your own filters. Use our flexible Screener to mix metrics like valuation, future growth, balance sheet strength and risks, or tap into our curated Investing Ideas for ready made shortlists built around clear themes.

Insmed (INSM)

Overview: Insmed is a biopharmaceutical company that develops and sells treatments for serious and rare diseases, including lung infections and complex respiratory conditions, across the United States and international markets. Its pipeline also includes gene therapies and AI supported protein engineering projects aimed at hard to treat disorders.

Operations: Insmed generates about US$1.1 billion in revenue from developing and commercializing therapies for patients with rare diseases, with roughly US$969 million from the United States and US$169 million from international markets.

Market Cap: US$28.6 billion

Insmed gives you exposure to high value rare disease drugs at the same time as it experiments with AI in research and protein engineering. This fits neatly with an AI and automation theme without relying on big tech style work cultures. The story today turns on how effectively Insmed can build on strong respiratory products like Brinsupri, execute multiple late stage trials, and manage regulatory and payer hurdles that can affect timing and uptake. Analysts have set ambitious price targets, yet the stock is still loss making, has relied heavily on external funding, and has seen recent insider selling. For investors who can handle clinical and valuation risk, the next few years of launches and trial readouts will be crucial.

Insmed’s rare disease story is accelerating while many investors seem fixated on short term noise. Get the full 3 key rewards and 2 important warning signs and see what the current setup might be quietly signaling.

Vicor (VICR)

Overview: Vicor designs and manufactures high efficiency modular power components that convert and manage electrical power inside complex electronics, from data center AI chips and telecom hardware to factory automation, vehicles, and aerospace systems worldwide.

Operations: Vicor generates about US$474 million in revenue primarily from advanced or brick format power products, with roughly US$253 million from the United States, US$167 million from Asia Pacific, and US$52 million from Europe.

Market Cap: US$10.2b

Vicor sits at a key hardware bottleneck in AI and automation, supplying high efficiency power modules that feed power hungry data center and automotive platforms. Recent results show strong earnings momentum, a sharply higher backlog, and raised revenue guidance, which together suggest demand tied to AI compute build outs rather than purely speculative interest. At the same time, the stock trades on a rich P/E, relies meaningfully on volatile licensing income, and carries governance questions after significant insider selling and limited board refresh. For investors seeking exposure to the physical infrastructure behind AI while keeping an eye on valuation and execution risk, Vicor is a story that may warrant closer attention beyond the headlines about overworked software engineers.

Vicor’s AI power story is accelerating, while many investors remain focused on headline worries about valuation and licensing risk. Get the 3 key rewards and 3 important warning signs (2 are major!) and see what the current setup might be quietly flagging.

Seeking Alternatives Before The Crowd?

Fresh stock stories can pick up momentum fast, then move out of reach. Review these ideas while they are still under the radar.

• Target dependable cash flows and income stability by screening for companies in the 9 dividend fortresses.
• Spot early leadership in future critical materials by scanning the curated 28 best rare earth metal stocks.
• Explore grid and electrification demand with the focused 37 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com